CD82 Protein (CD82) (His tag)

Produktnummer ABIN7317388

Dieses Recombinant CD82-Protein wird in HEK-293 Cells produziert.

Kurzübersicht für CD82 Protein (CD82) (His tag) (ABIN7317388)

Target: CD82

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Reinheit: > 90 % as determined by reducing SDS-PAGE.

Produktdetails

Aufreinigungstag / Konjugat: Dieses CD82 Protein ist gelabelt mit His tag.

Verwendungszweck: Recombinant Human CD82/KAI-1 Protein (His Tag)

Sequenz: Gly 111-Leu 228

Produktmerkmale: A DNA sequence encoding the second extracellular domain of human CD82 (P27701-1) (Gly 111-Leu 228) was fused with a polyhistidine tag at the C-terminus and a signal peptide at the N-terminus.

Endotoxin-Niveau: < 1.0 EU per μg as determined by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Antigendetails

Target: CD82

Andere Bezeichnung: CD82/KAI-1

Hintergrund:

Background: CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.

Synonym: 4F9,C33,GR15,IA4,KAI-1,KAI1,R2,SAR2,ST6,TSPAN27

Molekulargewicht: 15 kDa

Pathways: p53 Signalweg